Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV001193903 | SCV001363071 | likely pathogenic | Familial cancer of breast | 2019-10-22 | criteria provided, single submitter | clinical testing | Variant summary: CDH1 c.321C>G (p.Tyr107X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as likely pathogenic and pathogenic by our laboratory. The variant was absent in 251250 control chromosomes (gnomAD). To our knowledge, no occurrence of c.321C>G in individuals affected with Breast Cancer and no experimental evidence demonstrating its impact on protein function have been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic. |
| Myriad Genetics, |
RCV003336328 | SCV004045180 | pathogenic | Hereditary diffuse gastric adenocarcinoma | 2023-06-08 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. |
| Fulgent Genetics, |
RCV005021486 | SCV005644333 | likely pathogenic | Familial cancer of breast; Blepharocheilodontic syndrome 1; Endometrial carcinoma; Hereditary diffuse gastric adenocarcinoma; Ovarian cancer | 2024-05-20 | criteria provided, single submitter | clinical testing |